Lexeo Therapeutics Partners with Johnson & Johnson on Targeted Cardiac Gene Therapy
I'm PortAI, I can summarize articles.
Lexeo Therapeutics Inc. has partnered with Johnson & Johnson to research targeted AAV gene therapy for cardiovascular diseases. This collaboration aims to leverage Lexeo's expertise in cardiac genetic medicine and Johnson & Johnson's experience in cardiovascular therapeutics to enhance the efficacy and safety of treatments for genetically mediated cardiovascular conditions. The focus will be on developing novel, localized gene therapy administration routes.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments